NEW YORK, June 10, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.So What: If you purchased PepGen securities during the Class Period you may be ...

Core Points - A shareholder class action lawsuit has been filed against PepGen Inc. alleging that the company made materially false and misleading statements regarding its business and operations [1] - The lawsuit specifically claims that PGN-EDO51 was less effective and safe than previously represented, and that the CONNECT2 study was inadequate for FDA approval [1] - As a result of these allegations, it is suggested that PepGen may halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-EDO51 [1] Legal Information - Shareholders who purchased PepGen shares between March 7, 2024, and March 3, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is August 8, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading statements and/ ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, inclusive. For more information, submit a form at PepGen Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-20 ...

PepGen Inc. PEPG announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in Phase 2 clinical development.The company voluntarily discontinued the development of PGN-EDO51 and intends to wind down all Duchenne muscular dystrophy (DMD)-)-related research and development activities.The decision is based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study of PGN-EDO51 in DMD patients amenable to exon 51 skipping.In ...

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights – Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – FREEDOM-DM1 data from 15 mg/kg cohort expected in the second half of 2025 – – CONNECT1-EDO51 data from 10 mg/kg cohort expected in the third quarter of 2025 – BOSTON— May 8, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-3819 ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PepGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 4, 2025, PepG ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  PepGen Inc ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether PepGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 4, 2025, PepGen issued ...

On Tuesday, PepGen Inc. PEPG announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company can review results from the 10 mg/kg cohort.The first two cohorts of the CONNECT1 study are fully enrolled and data from the 10 mg/kg cohort are expected during the third quarter of 2025. No new safety issues related to PGN-EDO51 have been observed since the company’s last safety update as of January 23, 2025.Als ...